vs
查尔斯河实验室（CRL）与因塞特（INCY）财务数据对比。点击上方公司名可切换其他公司
因塞特的季度营收约是查尔斯河实验室的1.3倍（$1.3B vs $994.2M），因塞特净利率更高（23.8% vs -27.8%，领先51.7%），因塞特同比增速更快（19.8% vs -0.8%），过去两年因塞特的营收复合增速更高（10.4% vs -0.9%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
因塞特是总部位于美国特拉华州威尔明顿的跨国制药企业，目前在北美、欧洲及亚洲多地设有生产基地与研发中心，专注于创新药物的研发、生产及商业化，为全球患者提供优质的治疗选择。
CRL vs INCY — 直观对比
营收规模更大
INCY
是对方的1.3倍
$994.2M
营收增速更快
INCY
高出20.6%
-0.8%
净利率更高
INCY
高出51.7%
-27.8%
两年增速更快
INCY
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $1.3B |
| 净利润 | $-276.6M | $303.3M |
| 毛利率 | — | — |
| 营业利润率 | -28.5% | 23.7% |
| 净利率 | -27.8% | 23.8% |
| 营收同比 | -0.8% | 19.8% |
| 净利润同比 | -28.9% | 91.7% |
| 每股收益（稀释后） | $-5.57 | $1.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLINCY
| Q1 26 | — | $1.3B | ||
| Q4 25 | $994.2M | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $984.2M | $1.1B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.0B | $1.0B |
净利润CRLINCY
| Q1 26 | — | $303.3M | ||
| Q4 25 | $-276.6M | $299.3M | ||
| Q3 25 | $54.4M | $424.2M | ||
| Q2 25 | $52.3M | $405.0M | ||
| Q1 25 | $25.5M | $158.2M | ||
| Q4 24 | $-214.5M | $201.2M | ||
| Q3 24 | $69.7M | $106.5M | ||
| Q2 24 | $94.1M | $-444.6M |
毛利率CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | — | 92.0% | ||
| Q3 25 | — | 92.8% | ||
| Q2 25 | — | 93.5% | ||
| Q1 25 | — | 93.0% | ||
| Q4 24 | — | 92.5% | ||
| Q3 24 | 34.6% | 92.4% | ||
| Q2 24 | 34.5% | 92.7% |
营业利润率CRLINCY
| Q1 26 | — | 23.7% | ||
| Q4 25 | -28.5% | 22.3% | ||
| Q3 25 | 13.3% | 32.5% | ||
| Q2 25 | 9.7% | 43.6% | ||
| Q1 25 | 7.6% | 19.5% | ||
| Q4 24 | -16.7% | 25.6% | ||
| Q3 24 | 11.6% | 12.8% | ||
| Q2 24 | 14.8% | -45.8% |
净利率CRLINCY
| Q1 26 | — | 23.8% | ||
| Q4 25 | -27.8% | 19.9% | ||
| Q3 25 | 5.4% | 31.1% | ||
| Q2 25 | 5.1% | 33.3% | ||
| Q1 25 | 2.6% | 15.0% | ||
| Q4 24 | -21.4% | 17.1% | ||
| Q3 24 | 6.9% | 9.4% | ||
| Q2 24 | 9.2% | -42.6% |
每股收益（稀释后）CRLINCY
| Q1 26 | — | $1.47 | ||
| Q4 25 | $-5.57 | $1.46 | ||
| Q3 25 | $1.10 | $2.11 | ||
| Q2 25 | $1.06 | $2.04 | ||
| Q1 25 | $0.50 | $0.80 | ||
| Q4 24 | $-4.17 | $0.90 | ||
| Q3 24 | $1.33 | $0.54 | ||
| Q2 24 | $1.74 | $-2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | — |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $3.2B | $5.6B |
| 总资产 | $7.1B | $7.3B |
| 负债/权益比越低杠杆越低 | 0.68× | — |
8季度趋势，按日历期对齐
现金及短期投资CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | $213.8M | $3.1B | ||
| Q3 25 | $207.1M | $2.5B | ||
| Q2 25 | $182.8M | $2.0B | ||
| Q1 25 | $229.4M | $1.9B | ||
| Q4 24 | $194.6M | $1.7B | ||
| Q3 24 | $210.2M | $1.3B | ||
| Q2 24 | $179.2M | $987.3M |
总债务CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — |
股东权益CRLINCY
| Q1 26 | — | $5.6B | ||
| Q4 25 | $3.2B | $5.2B | ||
| Q3 25 | $3.4B | $4.7B | ||
| Q2 25 | $3.4B | $4.2B | ||
| Q1 25 | $3.2B | $3.7B | ||
| Q4 24 | $3.5B | $3.4B | ||
| Q3 24 | $3.8B | $3.2B | ||
| Q2 24 | $3.7B | $3.0B |
总资产CRLINCY
| Q1 26 | — | $7.3B | ||
| Q4 25 | $7.1B | $7.0B | ||
| Q3 25 | $7.5B | $6.3B | ||
| Q2 25 | $7.6B | $5.8B | ||
| Q1 25 | $7.6B | $5.7B | ||
| Q4 24 | $7.5B | $5.4B | ||
| Q3 24 | $8.0B | $5.0B | ||
| Q2 24 | $7.9B | $4.7B |
负债/权益比CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | 0.68× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | — |
| 自由现金流经营现金流 - 资本支出 | $58.6M | — |
| 自由现金流率自由现金流/营收 | 5.9% | — |
| 资本支出强度资本支出/营收 | 8.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $518.5M | — |
8季度趋势，按日历期对齐
经营现金流CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | $147.5M | $543.3M | ||
| Q3 25 | $213.8M | $559.4M | ||
| Q2 25 | $204.6M | $44.7M | ||
| Q1 25 | $171.7M | $266.1M | ||
| Q4 24 | $159.4M | $381.2M | ||
| Q3 24 | $251.8M | $310.9M | ||
| Q2 24 | $193.5M | $-575.6M |
自由现金流CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | $58.6M | — | ||
| Q3 25 | $178.2M | — | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | — | ||
| Q3 24 | $213.1M | — | ||
| Q2 24 | $154.0M | — |
自由现金流率CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 15.0% | — |
资本支出强度CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.8% | — |
现金转化率CRLINCY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.82× | ||
| Q3 25 | 3.93× | 1.32× | ||
| Q2 25 | 3.91× | 0.11× | ||
| Q1 25 | 6.74× | 1.68× | ||
| Q4 24 | — | 1.89× | ||
| Q3 24 | 3.61× | 2.92× | ||
| Q2 24 | 2.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
INCY
暂无分部数据
